The gap between early-stage promise and mid-stage momentum is where many medical device companies begin to struggle. At the recent Medtech MVP conference, I had the opportunity to share the stage with other MedTech leaders to discuss what it takes to make it from promising concept to positive market impact. Below are some reflections from this great discussion and personal experiences.
1. The Valley of Death is real, but can be managed
MedTech has a uniquely long and expensive path from prototype to reimbursed product. Most founders understand this intellectually, but it is much more difficult to structure milestones, burn rate, and investor narrative around the actual shape of this journey.
The companies that survive the valley aren't necessarily better funded. They're better sequenced. They know which milestone(s) unlocks the next check, and they ruthlessly prioritize those milestones over everything else. "Technically works" and "clinically proven" are separated by years, dollars, and an entirely different kind of evidence. The gap between them is where many companies fail.
2. FDA is a milestone, not a finish line
Many early-stage founders treat regulatory clearance as the goal. Experience tells us that it is a necessary, but insufficient part of achieving success. While the regulatory pathway (510(k), De Novo, PMA) may determine your timeline to commercialization, your product and clinical differentiators will be the major drivers of your adoption profile. Simply getting to market quickly often does not translate to rapid product diffusion.
The best medtech operators combine their regulatory strategy with their product and clinical strategy. They don’t look at it as a compliance exercise, but as a strategic exercise that determines the right approach to maximize adoption in the market.
3. Build a progressive evidence stack to convince the decision-makers who matter most
Early investors want clinical proof of concept. Payers want health-economic data. Guideline authors want randomized controlled trials. Clinicians want to ensure better outcomes for patients. If you only optimize for one, you can end up with a cleared device that no system will actually pay for or that results in very little adoption. Instead, structure deliverables to build evidence progressively so value compounds.
- Early investor evidence: clinical proof of concept, understanding of mechanism of action, repeatability. Data that derisks the next clinical phase is key.
- Regulatory evidence: Substantial equivalence or clinical performance data to meet agency bar.
- Payer evidence: Health-economic outcomes, cost offsets, comparative effectiveness.
- Clinical guideline evidence: Randomized trials, peer-reviewed publication, independent replication.
- Clinician evidence: Meaningful patient outcomes and improvements that do not disrupt current workflow.
4. The skills that get you to Series A can be the skills that stall you at Series B
This is one of the hardest conversations and often one of the most important. The idealist founder-led team that takes a device from concept to first-in-human is a different organism than the team required to execute a pivotal trial, build out commercial infrastructure, and navigate a complex reimbursement landscape.
Hiring ahead of the curve is expensive, but hiring behind it can cost you more in time, in board confidence, and in the quality of the decisions being made. The inflection points are usually around product strategy, market access, clinical strategy, regulatory strategy, and commercial readiness. Get experienced operators in these seats earlier than feels comfortable, but consider fractional expert help where you can, to maintain optionality and keep overhead low.
5. Your key opinion leaders and your mainstream customers are often different
Early adopter physicians are risk-tolerant, curious, often academically motivated, and deeply committed to evidence generation. They're invaluable. And they are almost nothing like the community physician or the integrated delivery network you'll need for adoption at scale.
The commercial transition from early adopter to mainstream requires a completely different sales motion, a different support model, different training infrastructure, and often a different pricing strategy. Companies that don't plan for this can lose their early momentum at exactly the moment they want to be accelerating. Getting the commercial model or hiring profile wrong is expensive to unwind, and restructuring sales distribution mid-launch can cost you years of momentum.
6. Know when to change course and when to hold
Every medtech company faces moments when the data, the market, or the competitive landscape seems to signal a significant change is needed: new indications, a different delivery mode, a revised commercial target. The discipline is in distinguishing real signals from noise generated by investor pressure, competitive anxiety, or short-term setbacks.
Successful pivots tend to share one characteristic: they're made from a position of insight, not desperation. The companies that pivot well have done the customer discovery and relationship building work, the economic analysis, and the competitive mapping. They know the landscape inside and out. The companies that pivot poorly are reacting to individual moments, like a difficult board meeting, rather than overarching trends, and lack the clarity and foundational knowledge to know when a reaction is just that, and not a strategic shift.
7. Keep culture and mission strong through growth
The culture of a 15-person startup, where every person knows the patient story behind the device and makes decisions accordingly, is difficult to maintain as you scale. When you have 150 employees, a quality management system, a notified body in your building, and a board demanding commercial metrics, the mission can start to feel abstract.
The founders and executives who navigate this well are intentional about it. They bring patient outcomes into the boardroom. They make sure the people building the device can still articulate why it matters. They understand that culture isn't a perk or a perquisite, it's the organizational immune system that keeps short-term commercial pressure from corrupting long-term clinical and cultural integrity.
The Bottom Line
The companies that successfully cross the chasm from early stage to mid stage aren't the ones with the best ideas, sketched onto napkins by brilliant founders leading small, but eager teams ready to make them happen. They're the ones with the clearest strategic discipline about product direction, about clinical evidence, about milestone sequencing and capital preservation, about the key in-house roles to hire and when to partner with experts, and about their mission.
The valley in between Series A and meaningful market impact is narrow and unforgiving, but it’s also incredibly worthwhile to pass through. Bon voyage. And if you need help navigating it, reach out.
